KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Treasury Shares (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 13 years of Treasury Shares data on record, last reported at $3.8 million in Q4 2024.

  • For Q4 2024, Treasury Shares rose 1595.13% year-over-year to $3.8 million; the TTM value through Dec 2024 reached $3.8 million, up 1595.13%, while the annual FY2024 figure was $3.8 million, 1595.13% up from the prior year.
  • Treasury Shares reached $3.8 million in Q4 2024 per IONS's latest filing, up from $226000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.8 million in Q4 2024 and bottomed at $59000.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $1.8 million, with a median of $1.9 million recorded in 2020.
  • Peak YoY movement for Treasury Shares: crashed 97.51% in 2021, then surged 4588.14% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $2.4 million in 2020, then plummeted by 97.51% to $59000.0 in 2021, then soared by 4588.14% to $2.8 million in 2022, then plummeted by 91.83% to $226000.0 in 2023, then soared by 1595.13% to $3.8 million in 2024.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $3.8 million in Q4 2024, $226000.0 in Q4 2023, and $2.8 million in Q4 2022.